Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

NCT01527487 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

OTHER

Sponsor class

Conditions

HER2 Negative Breast Cancer

Interventions

DRUG: Eribulin
DRUG: Cyclophosphamide
DRUG: Docetaxel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]